A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Have a diagnosis of plaque-type psoriasis for at least 6 months before the firstadministration of study drug

• Have a Psoriasis Area and Severity Index (PASI) greater than (>)10 or Body SurfaceArea (BSA) >10 at screening and at baseline

• Have a Dermatology Life Quality Index (DLQI) >10 at screening and at baseline

• Agree not to receive a live virus or live bacterial vaccination during the study, orwithin 3 months after the last administration of study drug; for information onBacille Calmette-Guérin (BCG) vaccination, agree not to receive a BCG vaccinationduring the study, or within 12 months after the last administration of study drug

• No dipstick detection of proteins or glucose in urine. If there are signs of proteinsand/or glucose on urine test strip, the urine sample must be analyzed centrally. Here,protein and glucose levels must not exceed trace levels, example, <=(+); one re-test (central urine analysis) is allowed

Exclusion Criteria:

• Has a history or current signs or symptoms of severe, progressive, or uncontrolledliver or renal insufficiency, significant cardiac, vascular, pulmonary,gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, ormetabolic disturbances

• Participants with nonplaque forms of psoriasis (for example, erythrodermic, guttate,or pustular) or with current drug-induced psoriasis (for example, a new onset ofpsoriasis or an exacerbation of psoriasis from beta blockers, calcium channelblockers, or lithium)

• Known allergies, hypersensitivity, or intolerance to Guselkumab or its excipients

• Is pregnant, or breast-feeding, or planning to become pregnant while enrolled in thisstudy or within 12 weeks after the last dose of study drug

• Any condition for which, in the opinion of the investigator, participation would notbe in the best interest of the participant (for example, compromise the well-being) orthat could prevent, limit, or confound the protocol-specified assessments